Document is current
Any future updates will be listed below
-
Authors
Eloranta, M. L.
Nygren, P.
Larsson, R.
Loskog, A.
Woodworth, N.
Hultqvist, M.
Svensson, Richard
Gravenfors, Ylva
Rönnblom, L.
Fryknäs, Mårten
-
Funding
Funding for this research was provided by:
Uppsala University
- License Information
-
More Information
Article History
Received: 2 December 2024
Accepted: 28 January 2026
First Online: 12 February 2026
Declarations
:
: R.L., P.N., and M.F. are minor shareholders and members of the board in Repos Pharma AB, a Swedish R&D company specializing in drug repositioning, including development of MBZ. AL is Chairman of Repos Pharma AB. All other authors have declared no conflicts of interest.
